Horizon Therapeutics Public (HZNP) Scheduled to Post Quarterly Earnings on Wednesday

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) is scheduled to post its quarterly earnings results before the market opens on Wednesday, May 4th. Analysts expect Horizon Therapeutics Public to post earnings of $1.15 per share for the quarter. Horizon Therapeutics Public has set its FY 2022 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last released its earnings results on Tuesday, March 1st. The biopharmaceutical company reported $1.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.14. Horizon Therapeutics Public had a return on equity of 26.66% and a net margin of 16.57%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $995.90 million. During the same quarter in the previous year, the business posted $1.28 EPS. The business’s revenue for the quarter was up 36.1% on a year-over-year basis. On average, analysts expect Horizon Therapeutics Public to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

NASDAQ:HZNP opened at $103.47 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.16 and a quick ratio of 2.90. Horizon Therapeutics Public has a fifty-two week low of $83.42 and a fifty-two week high of $120.54. The stock’s 50-day moving average is $104.82 and its two-hundred day moving average is $103.88. The stock has a market cap of $23.71 billion, a PE ratio of 46.40, a price-to-earnings-growth ratio of 1.49 and a beta of 1.12.

In related news, CFO Paul W. Hoelscher sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 20th. The stock was sold at an average price of $114.71, for a total value of $5,735,500.00. Following the completion of the sale, the chief financial officer now directly owns 1,049 shares in the company, valued at approximately $120,330.79. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Timothy P. Walbert sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, January 31st. The stock was sold at an average price of $91.85, for a total value of $9,185,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 655,624 shares of company stock valued at $69,265,270. Corporate insiders own 2.50% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Morgan Stanley lifted its holdings in shares of Horizon Therapeutics Public by 11.2% during the second quarter. Morgan Stanley now owns 753,642 shares of the biopharmaceutical company’s stock worth $70,572,000 after buying an additional 76,061 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Horizon Therapeutics Public by 1.4% during the fourth quarter. California State Teachers Retirement System now owns 388,851 shares of the biopharmaceutical company’s stock worth $41,903,000 after buying an additional 5,407 shares during the last quarter. Weiss Multi Strategy Advisers LLC lifted its holdings in shares of Horizon Therapeutics Public by 4.2% during the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 41,818 shares of the biopharmaceutical company’s stock worth $4,506,000 after buying an additional 1,699 shares during the last quarter. LPL Financial LLC lifted its holdings in shares of Horizon Therapeutics Public by 6.3% during the fourth quarter. LPL Financial LLC now owns 29,239 shares of the biopharmaceutical company’s stock worth $3,151,000 after buying an additional 1,738 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Horizon Therapeutics Public by 12.7% during the fourth quarter. Legal & General Group Plc now owns 11,876 shares of the biopharmaceutical company’s stock worth $1,280,000 after buying an additional 1,335 shares during the last quarter. Institutional investors own 88.11% of the company’s stock.

Several equities analysts have weighed in on the company. Morgan Stanley lifted their target price on Horizon Therapeutics Public from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 2nd. Zacks Investment Research raised Horizon Therapeutics Public from a “strong sell” rating to a “hold” rating and set a $104.00 price target for the company in a research note on Thursday, March 3rd. Wells Fargo & Company reissued a “buy” rating and issued a $133.00 price target on shares of Horizon Therapeutics Public in a research note on Friday, April 8th. Piper Sandler lowered their price target on Horizon Therapeutics Public from $143.00 to $133.00 in a research note on Wednesday, January 26th. Finally, Oppenheimer assumed coverage on Horizon Therapeutics Public in a research note on Monday, March 14th. They issued an “outperform” rating and a $140.00 price target for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $133.67.

About Horizon Therapeutics Public (Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Further Reading

Earnings History for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.